This paper summarises Switzerland’s experience with limited medical use of LSD, MDMA and psilocybin since 2014—reporting over 1,000 exemption approvals and an estimated 2,000–3,000 treatments—and provides an overview of application procedures, indications, treatment settings and phases, plus recommendations on therapist training, ethics and quality assurance for integrating psychedelics‑assisted psychotherapy into clinical practice.
- Published
- Journal
- Die Psychotherapie
- Authors
- Aicher, H. D., Schmid, Y., Gasser, P.